Bladder Cancer Market and Forecast Analysis

Bladder Cancer Market and Forecast Analysis

  • July 2018 •
  • 199 pages •
  • Report ID: 5780028 •
  • Format: PDF
Disease Overview
Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections. Urothelial carcinoma, also known as transitional cell carcinoma, accounts for over 90% of bladder cancers. Approximately three-quarters of urothelial carcinoma patients initially present with non-muscle invasive bladder cancer (NMIBC), which is associated with a relatively good prognosis. However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.

Market Snapshot

The value of the bladder cancer market is projected to reach $4.8bn by 2025, with growth driven by immunotherapies.
Pharmacological treatment of urothelial bladder cancer is dominated by platinum-based chemotherapy regimens.
Between 2017 and 2037, incident cases of bladder cancer will increase by over 40% in the US, Japan, and five major EU markets.
Immunotherapy developers will seek label expansions in a variety of treatment settings to differentiate their products.
Late-phase targeted therapies will look to address needs not met by immunotherapies.